GlaxoSmithKline's (GSK) hopes of a return to growth for its embattled respiratory division in 2016 have been knocked back after the failure of a large-scale trial of new drug Breo/Relvar.

means the drug is unlikely to reach GSK’s previous forecast sales of $1.6 billion by 2020. Developed with US respiratory specialist firm Innoviva, Relvar/Breo Ellipta recorded sales of £257 ...

Teva Pharmaceutical Industries Ltd. ADR-0.28% $24.91B ...

GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for fibrotic diseases and osteoarthritis. The two-stranded collaboration will ...

Dec 9 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple ...

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the ...